Effects of omeprazole on plasma levels of raltegravir

Clinical Infectious Diseases

Volumn 48, Issue 4, 2009, Pages 489-492

  Iwamoto, Marian ^a   Wenning, Larissa A ^a   Nguyen, Bach Yen ^a   Teppler, Hedy ^a   Moreau, Allison R ^a   Rhodes, Rand R ^a   Hanley, William D ^a   Jin, Bo ^a   Harvey, Charlotte M ^a   Breidinger, Sheila A ^a   Azrolan, Neal ^a   Farmer Jr , H Frank ^b   Isaacs, Robin D ^a   Chodakewitz, Jeffery A ^a   Stone, Julie A ^a   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Covance Clinical Research Unit ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; INTEGRASE INHIBITOR; OMEPRAZOLE; PLACEBO; RALTEGRAVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DISPOSITION; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STOMACH PH; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PLASMA; PYRROLIDINONES; YOUNG ADULT;

EID: 58749102754     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596503     Document Type: Article

References (9)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A working group of the Office of AIDS Research Advisor Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 28 March 2008.
2. ISENTRESS (raltegravir) [package insert]. Merck & Co., 2007.
3. Iwamoto M, Kassahun K, Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol 2008; 48:209-14.
4. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29:769-84.
5. Merschman SA, Vallano PT, Wenning LA, Matuszewski BK, Woolf EJ. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 857:15-24.
6. Lakebakaar G, Tom W, Lakebakaar D, et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109:471-3.
7. Lakebakaar G, Quadros E, Beidas S, et al. Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109:502-4.
8. Steigbigel MD, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-54.
9. Grinsztejn B, Nguyen B-Y, Katlama C, et al. 48 week efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract H713]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago).Washington, DC: American Society for Microbiology, 2007.